Table 2.
Medications administered to patients with Behçet’s disease in the RISE registry
| Medications | Total patients (N = 1323) | |
|---|---|---|
| No therapy recorded | 111 (8.4) | |
| Colchicine | 728 (55.0) | |
| Dapsone | 62 (4.7) | |
| Glucocorticoids | Any prednisone or equivalenta | 895 (67.6) |
| csDMARDs | Azathioprine | 418 (31.6) |
| Methotrexate | 288 (21.8) | |
| Hydroxychloroquine | 117 (8.8) | |
| Sulfasalazine | 53 (4.0) | |
| Mycophenolate | 31 (2.3) | |
| Leflunomide | 26 (2.0) | |
| Cyclosporine | 23 (1.7) | |
| Tacrolimus | 11 (0.83) | |
| Cyclophosphamide | < 10 | |
| Minocycline | < 10 | |
| Biologics-TNFi | Infliximab | 192 (14.5) |
| Adalimumab | 187 (14.1) | |
| Etanercept | 92 (6.9) | |
| Certolizumab | 30 (2.3) | |
| Golimumab | 20 (1.5) | |
| Biologics-non-TNFib | 59 (4.5) | |
| Targeted small molecules | Tofacitinib | 11 (0.80) |
| Baricitinib | < 10 | |
| Apremilast | 42 (3.2) | |
| Anticoagulants | Warfarin | 39 (2.9) |
| Rivaroxaban | 27 (2.0) | |
| Apixaban | 15 (1.1) | |
| Enoxaparin | 11 (0.8) | |
| Dabigatran | < 10 | |
| Edoxaban | 0 (0.0) | |
RISE Rheumatology Informatics System for Effectiveness, csDMARDs conventional disease modifying anti-rheumatic drugs, TNFi tumor necrosis factor inhibitors
For privacy protection, we reported no cell sizes < 10
aPrednisone or equivalent included prednisone and other oral and intravenous steroids
bBiologics-non-TNFi include rituximab, abatacept, tocilizumab, ustekinumab, anakinra, and secukinumab